Nov 30, 2022 / 03:30PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Thank you, guys, for joining us. Royalty Pharma management with us really excited, but I'll turn it over to Pablo and Terry to maybe kick things off, and we'll jump right in.
Pablo Legorreta - Royalty Pharma plc - Founder, Chairman of the Board & CEO
Sure. Thank you Umer for the invitation to join you this morning. And I thought it made sense just for me to spend a few minutes talking about why we're so excited about our business, the current situation we're in, in this interesting market for us. And as you mentioned, with me is Terry Coyne, our Chief Financial Officer. So I'll just start by providing some perspective on Royalty Pharma. We are the leader in the biopharma royalty market. We own a portfolio of about 45 approved and development stage products. Looking at sort of the recent financial performance, we've delivered 18% of top line growth this year. And this is a bit higher than the 13% Adjusted Cash Receipts compound annual growth
Royalty Pharma PLC at Evercore ISI HealthCONx Conference (Virtual) Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers